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Edited by Veli-Pekka LehtoAbstract TheNK-lysin derived peptideNK-2 is a potent antibac-
terial, but non-toxic to a human keratinocyte cell line and of low
hemolytic activity. Its target selectivity is based upon a strong
binding preference to membranes containing anionic phospholip-
ids, which are normally not found on the surface of human cells.
Here, we analyzed the interaction of NK-2 with normal human
lymphocytes and seven diﬀerent human cancer cell lines and dem-
onstrate that some of these cells expose negatively charged surface
phosphatidylserine (PS), which presumably facilitates killing of
the cells by NK-2. This is underlined by the speciﬁc intercalation
of the peptide into PS-containing liposomes analyzed by ﬂuores-
cence-resonance energy transfer spectroscopy.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Chemotherapeutic agents are commonly used as anti-cancer
drugs but they frequently aﬀect normal human cells and thus
cause severe side eﬀects. Neuroblastoma (NB) for instance is
a neuroectodermal tumor of infancy, associated with the high-
est mortality rate of all childhood tumors [1]. Despite surgery
and chemotherapy, which is routinely applied and has been
improved over the last years, prognosis of advanced tumors
still is very poor [2]. Consistently, there is an urgent need for
new therapeutic agents.
Natural antimicrobial peptides, also referred to as host
defense peptides, and synthetic derivatives thereof have gained
interest as potential anti-cancer agents [3–5]. They are part of
the innate immunity of a variety of multicellular organisms
ranging from insects to man [6,7]. In contrast to conventional
antibiotics, they act by a physical disturbance or destruction of
the barrier function of the bacterial membrane without
involvement of a speciﬁc receptor [7,8]. Some have been suc-
cessfully used to eliminate, e.g., prostate tumor cells in vitro
[9], and others were also very eﬀective in vivo in the elimina-Abbreviations: FACS, Fluorescence-activated cell sorter; FRET, ﬂuo-
rescence-resonance energy transfer spectroscopy; NB, neuroblastoma;
PC, phosphatidylcholine; PE, phosphatidylethanolamine; PS, phos-
phatidylserine; PI, propidium iodide
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doi:10.1016/j.febslet.2005.09.084tion of leukemia, ascite and ovarian tumors [10,11]. However,
the molecular basis for a selective targeting of cancer cells as
well as the mechanism of cell killing remain important
unsolved questions.
We have derived a potent peptide (termed NK-2 [12]) from
the cationic core region of NK–lysin, an antibacterial eﬀector
protein from porcine NK- and T-cells [13,14] with homologs
found in human [15], cattle [16], and an ancient ancestor of this
protein family in a pathogenic amoeba [17]. NK-2 consists of 27
amino acid residues with an overall positive net charge and
adopts an amphipathic, a-helical secondary structure upon
membrane interaction [12,18]. NK-2 is highly active against
Gram-negative and Gram-positive bacteria, clinical isolates
of Candida albicans [12], against the intracellular parasite Try-
panosoma cruzi [19], and is also an eﬀective neutralizing agent
of bacterial endotoxin [20]. On the other hand, human erythro-
cytes, keratinocytes [12], and glioblastoma cells [19] have been
found to be protected against cytotoxic NK-2 eﬀects. Because
of this selectivity for bacteria over normal human cells [12],
NK-2 may be of therapeutic value as a peptide antibiotic.
The selectivity of NK-2 could be assigned to diﬀerences in
the membrane phospholipid composition of the target cells
[18]. Whereas the bacterial cytoplasmic membrane is charac-
terized by a signiﬁcant amount of negatively charged phospho-
lipids, mainly phosphatidylglycerol, the human cell plasma
membrane surface consists of the zwitterionic choline phos-
pholipids PC and sphingomyelin and almost lacks anionic
phospholipids [21,22].
Negatively charged phosphatidylserine (PS), a constituent of
the inner layer of human cytoplasmic membranes, can be
translocated to the surface of cells during loss of membrane
asymmetry [23]. Surface exposed PS then serves as a marker
for the clearance of these cells from the bloodstream by mono-
cytes and macrophages [24], e.g., on pathological or aged
erythrocytes [25] and apoptotic cells [26]. Though it is not well
recognized, it has been shown, that also various tumor cells
have elevated surface levels of negatively charged phospholip-
ids, i.e., PS [27,28]. It is suggestive that surface-exposed PS ren-
der these cells susceptible to killing by cationic, membranolytic
peptides like NK-2 [29].
Here, we compare the cytotoxic activity of the NK-lysin de-
rived peptide NK-2 against normal human lymphocytes and
seven diﬀerent human cancer cell lines (two NB, one colorectal
adenocarcinoma, one lymphoma, and three leukemia cell
lines). We demonstrate that NK-2 selectively kills some cancer
cells and that this killing activity correlates with the membraneblished by Elsevier B.V. All rights reserved.
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and the capacity of the peptide to intercalate into PS-contain-
ing model membranes.2. Materials and methods
2.1. Peptides
NK-2 was synthesized with an amidated C–terminus (KILRG
VCKKI MRTFL RRISK DILTG KK-NH2) and obtained from
WITA GmbH (Berlin, Germany) in a purity grade >95% [18]. Melittin
(in HPLC-grade) was purchased as synthetic peptide from Sigma
(Deisenhofen, Germany) und used without further puriﬁcation.
2.2. Lipids
3-sn-Phosphatidylcholine (PC), 3-sn-phosphatidyl-L-serine (PS)
from bovine brain and sphingomyelin from chicken egg yolk were ob-
tained from Avanti Polar Lipids (Alabaster, USA).
2.3. Culture and harvesting of human cell lines
Cell lines used were the NB LA-N-1 (provided by R. Bredehorst, Uni-
versity of Hamburg) and SH-SY5Y cells (provided by C. Schaller, Uni-
versity of Hamburg), colorectal adenocarcinoma cancer cells (SW480,
ATCC CCL-228), the lymphoma cell line U-937 [30], and the leukemia
cell lines K-562 (derived from chronic myelogenous leukemia), Jurkat
andMOLT-4 (bothderived fromacute lymphoblastic leukemia; all three
a generous gift fromDr. J. Minowada, Hayashibara Biochemical Labo-
ratories, Okayama, Japan). Normal human lymphocytes were puriﬁed
from heparinized peripheral blood obtained from healthy adults (aged
38–40 years) by Lymphosepar I (Immuno-biological Laboratories,
Gumma, Japan) following the instructions of the manufacturer. Cells
were cultured in RPMI 1640, supplemented with 10% heat-inactivated
FCS, L-glutamine, penicillin, and streptomycin at 37 C in a humidiﬁed
atmosphere at 5% CO2. Cells were harvested by centrifugation (U-937,
K-562, Jurkat, and MOLT-4) or by trypsin/EDTA (5 ml, 1· in HBSS,
Gibco) treatment (LA-N-1, SH-SY5Y, and SW480), washed, and ﬁnally
resuspended in the respective buﬀer at indicated density.
2.4. Cytotoxicity assays
2.4.1. PI-uptake assay. Various dilutions of peptides (20 ll, diluted
from stock solutions in buﬀer) or buﬀer alone (as a negative control)
were given to the cell suspensions in 10 mM HEPES, 5 mM KCl,
150 mM NaCl, pH 7.4, (50 ll, 1 · 105). The mixtures were incubated
for 30 min at 37 C. Then, propidium iodide (PI; 5 ll, 100 lg/ml,
R&D Systems GmbH, Wiesbaden, Germany) was added and the sus-
pension was further incubated for 5 min at room temperature in the
dark. The reaction mixtures were diluted in ice-cold buﬀer and ana-
lyzed with a ﬂuorescence-activated cell sorter Calibur (FACSCalibur;
Becton–Dickinson, Heidelberg, Germany) ﬂow cytometer with com-
puter-assisted evaluation of data (CellQuest software). Cytotoxicity
(%cytox) was calculated from the percentage of PI positive cells in buf-
fer alone (PIb) and in the presence of peptides (PIexp): %cytox = 100 ·
((PIexp  PIb)/(100  PIb)).
2.4.2. Cell proliferation assays. Cell viability was determined using
two diﬀerent cell proliferation assays, which are based on the cellular
conversion of a tetrazolium salt into a formazan product.
(a) Freshly harvested LA-N-1 cells were suspended in medium
(RPMI 1640/10% FCS) to a density of 5 · 105 or 1 · 105 cells/ml,
respectively. This suspension (100 ll) was ﬁlled in each well of a sterile
ﬂat-bottom 96-well microtitre plate. After incubation at 37 C in a
humidiﬁed atmosphere with 5% CO2 for 24 h, the medium was
removed. A 2-fold serial dilution of peptides, in medium or in a mix-
ture (v/v) of 10% medium and 90% PBS, pH 7.4 were added to the
wells (100 ll each) and subsequently incubated for further 20 h or
30 min, respectively. In the latter case, PBS was replaced by medium
after the incubation period. As controls, medium or medium/PBS
was added to wells loaded with cells (=100% viability) and to wells
without cells (=0% viability). For determination of cell viability,
10 ll of MTT solution (Sigma, Deisenhofen, Germany) was added to
each well and subsequently incubated for 4 h at 37 C. Formazan crys-
tals were dissolved by adding acid isopropanol (100 ll) to each well,
and the extinction was measured using a microtitre-plate reader at
absorption and reference wavelengths of 540 and 630 nm, respectively.(b)Normal human lymphocytes,K-562,MOLT-4, orJurkat cells were
sedimentedby centrifugation (1000 rpm, 10 min) andwashed three times
with RPMI 1640 free of the growth factors. Hundred ll of the resulting
cell suspension (5 · 104 cells) were dispensed into each well of a 96-well
plate.Tenll ofNK-2 (two serial dilutions)was added to cell suspensions.
Cell growthwas detected after incubation for 24 h at 37 Cusing aCellT-
iter 96 Non-Radioactive Cell Proliferation Assay kit (Promega, Madi-
son, WI, USA). Dye solution (15 ll) was added to each well and the
plate was incubated for 2 h at 37 C in the case of K-562 and for 4 h in
the case of lymphocytes, Jurkat andMOLT-4. The absorbance of forma-
zan product at 490 nm was recorded using a 96-well plate reader (Inter-
MedImmunomini NJ-2300, InterMed, Japan). The data were calculated
as a percentage of the control (untreated) samples. Seven independent
experiments were carried out for each cell line and each peptide concen-
tration.
2.5. Annexin V-binding assays
2.5.1. FACS analysis. Cells (100 ll, 1 · 105) suspended in 10 mM
HEPES, 5 mM KCl, 150 mM NaCl, 1 mM MgCl2, 1.8 mM CaCl2, pH
7.4, were incubated with ﬂuorescein-labeled annexin V (5 ll, R&D Sys-
tems GmbH, Wiesbaden, Germany) for 15 min at 4 C in the dark. The
mixtures were diluted in ice-cold buﬀer and analyzed with a FACSCali-
bur (Becton–Dickinson, Heidelberg, Germany) ﬂow cytometer (FL-1)
with computer-assisted evaluation of data (CellQuest software).
2.5.2. Spectroﬂuorometric analysis. Cells (1 · 106/ml) were washed
twice with annexin V-binding buﬀer (PBS containing 2 mM MgCl2
and 2.5 mM CaCl2, pH 7.4). Hundred ll of the cell suspension (10
5
cells) were incubated with 2 ll FITC-conjugated annexin V (Annexin
V FITC Apoptosis Detection Kit, BioVision, Mountain View, CA,
USA) for 15 min at 4 C in the dark. The cells were washed twice with
annexin-binding buﬀer and resuspended in 100 ll of the same buﬀer.
FITC-annexin V bound to the cell surface was detected spectroﬂuori-
metrically at kex = 486 nm and kem = 530 nm using a Fluoromark ﬂuo-
rescent microplate reader (BioRad, Hercules, CA, USA). Six
independent experiments were carried out for each cell line. The data
are presented as mean ± S.D.2.6. Microscopy
LA-N-1 cells were incubated in the presence of NK-2 (10 lM ﬁnal
concentration) or in buﬀer alone and stained with PI as described
for the cytotoxicity assay. Microscopic analysis was done with an Axi-
oskop in connection with the AxioCam MRm camera and AxioVision
3.1 software (all obtained from Zeiss, Jena, Germany).2.7. Fluorescence resonance energy transfer
The ﬂuorescence resonance energy transfer (FRET) assay was per-
formed at 37 C as described earlier in more detail [31]. Brieﬂy, lipo-
somes made of PC, PS or indicated molar mixtures thereof, doubly
doped with ﬂuorescently labeled phosphatidylethanolamine (PE)
(N-(7-nitrobenz-2-oxa-1,3-diazol-4yl)-PE (NBD-PE) and N-(lissamine
rhodamine B sulfonyl)-PE (Rh-PE) (Molecular Probes, Eugene, OR,
USA)) were prepared in buﬀer (20 mM HEPES, 150 mM NaCl, pH
7.4) and ﬁlled into the cuvette (1 ml, ﬁnal lipid concentration 10 lM)
of a ﬂuorescence spectrometer (SPEX F1T11, SPEX Instr., Edison,
NY, USA). NBD-PE was excited at 470 nm and the NBD-donor
and Rh-acceptor emission was monitored at 531 and 593 nm, respec-
tively. After 50 s, NK-2 was added to the cuvette and the donor and
acceptor ﬂuorescence intensities were recorded over time. Intercalation
of the peptide into the liposomes resulted in probe dilution and as a
consequence in a lower FRET eﬃciency: the emission intensity of
the donor increases and that of the acceptor decreased. The FRET sig-
nal is presented as the quotient of the donor and acceptor emission
intensity (Idonor/Iacceptor).3. Results
3.1. Cancer cell killing by NK-2
We used two diﬀerent types of assays to determine the cyto-
toxic activity of the peptide NK-2: (i) a PI-uptake assay with
cells suspended in buﬀer, (ii) cell proliferation assays with
020
40
60
80
100
Vi
ab
le
 c
el
ls 
(%
 of
 co
ntr
ol)
0.1 1 10 100
40
60
80
100
A
B
6130 H. Schro¨der-Borm et al. / FEBS Letters 579 (2005) 6128–6134adherent cells in 10% medium/90% buﬀer or in complete med-
ium containing 10% serum. Incubation times were 30 min for
cells in buﬀer and 24 h for cells in medium. Using the PI-up-
take assay cancer cell lines were killed by NK-2 with LD50 val-
ues ranging from 1 to 4 lM with the exception of U-937 cells
with an estimated LD50 of 30 lM (Fig. 1A). In contrast to the
selective cytotoxic activity of NK-2, bee venom melittin, which
we used frequently as a control peptide, was eﬀective against
all cell lines at a similar low concentration (Fig. 1B). A kinetic
analysis of NK-2 cytotoxicity on LA-N-1 cells revealed a very
fast killing reaction. It was completed already within 5 min
after the addition of suﬃciently high concentrations (2 lM)
of peptide (Fig. 1C). NK-2 was also very eﬀective against
adherently growing LA-N-1 cells (Fig. 2A). Cells incubated
in 90% buﬀer were killed at only slightly lower peptide concen-
trations than cells incubated in complete medium including
serum. Furthermore, we analyzed the cytotoxic activity of**
0
20
40
60
80
100
SW480
U-937
SH-SY5Y
LA-N-1
0
20
40
60
80
100
Cy
to
to
xic
ity
 (%
 of
 co
ntr
ol)
0.01 0.1 1 10
Peptide concentration (µM)
A
B
0
20
40
60
80
100
0 10 20 30 40 50 60
Time (min)
C
***
*** ***
***
***
Fig. 1. Cytotoxic activity of NK-2 (A) and melittin (B) against NB
cells (LA-N-1; SH-SY5Y), colorectal adenocarcinoma cancer cells
(SW480), and lymphoma cancer cells (U–937) determined by the
PI-uptake assay. (C) Time course of NK-2 induced killing of NB cells.
LA-N-1 cells were incubated with various peptide concentrations (0.2,
0.7, 2, and 7 lM NK-2; open, light grey, dark grey and ﬁlled circles,
respectively). At indicated time points, an aliqout of cells was taken,
stained with PI, and analyzed by ﬂow cytometry. The data presented
are the mean of two independent experiments each performed in
duplicates. For better visuality, error bars are shown only for
representative curves. P < 0.001 (**), P < 0.0001 (***).
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Fig. 2. Cytotoxic activity of NK-2 determined by cell proliferation
assays against (A) LA-N-1 cells in 90% buﬀer/10% medium (open
symbols) and in complete medium containing 10% serum (ﬁlled
symbols), and (B) against normal human lymphocytes (ﬁlled circles)
and cells of the leukemia cell lines K-562 (open diamonds), MOLT-4
(open triangles), and Jurkat (ﬁlled squares) in complete medium
containing 10% serum. The data presented are the mean of three (A)
and seven (B) independent experiments each performed in duplicates.NK-2 against primary cells, i.e., lymphocytes isolated from hu-
man blood, and three leukemia cell lines, again using a cell
proliferation assay in complete medium (Fig. 2B). Most strik-
ingly, normal lymphocytes were only marginally aﬀected even
at 100 lMNK-2. In contrast, the sensitivity of the three leuke-
mia cell lines to the action of NK-2 was rather diverse, with
Jurkat cells being three times more resistant than K-562 and
MOLT-4 cells.
3.2. NK-2 induces drastical changes in cellular morphology
Cell shape and morphology of LA-N-1 cells after incubation
with NK-2 (10 lM) were analyzed by microscopy (Fig. 3,
upper panel). In parallel, the viability of the cells was deter-
mined by uptake of the DNA intercalating ﬂuorescent dye
PI. The dye passes the damaged membrane of dead cells and
was visualized by ﬂuorescence microscopy (Fig. 3, lower
panel). Control cells, incubated in buﬀer alone, were unstained
by PI and showed normal morphology (Fig. 3A). However,
cells incubated in the presence of NK-2 were mostly stained
by PI (>80%), indicating a loss of the membrane barrier func-
tion, and had an signiﬁcantly altered morphology. We ob-
served a complete release of the cytoplasmic content leaving
only the PI-stained nucleus intact (Fig. 3B). In addition, cells
became elongated and they tended to loose their cellular integ-
rity (Fig. 3C) until total destruction (Fig. 3D).
3.3. Amount of cell surface PS
The relative amount of cell surface PS was determined by
binding of ﬂuorescein-labeled annexin V to the cells and subse-
quent FACS analysis (Fig. 4) or spectroﬂuorometric analysis
of the cells (Table 1). The shift in ﬂuorescence intensity of
Fig. 3. Morphological changes and PI uptake of LA-N-1 NB-cells after NK-2 treatment. LA-N-1 cells were incubated in buﬀer (A) or in the presence
of NK-2 (10 lM; B–D) for 30 min at 37 C, stained with PI, and analyzed by light microscopy (upper panel) and ﬂuorescence microscopy (lower
panel). NB-cells which took up PI appear bright under ﬂuorescent light.
Fig. 4. Determination of PS surface exposure by annexin V binding to human cancer cells. Cells were incubated with ﬂuorescein-labeled annexin V
(grey curves) or in buﬀer alone as controls (ﬁlled areas) and analyzed by ﬂow cytometry. Representative experiments each performed at least in
duplicates are shown.
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of the accessible membrane PS content. The ﬂuorescence signal
obtained for both NB cell lines (LA-N-1, SH-SY5Y) and the
colon carcinoma cell line SW480 indicated a signiﬁcantamount of bound annexin, i.e., surface exposed PS. U–937
cells, however, showed only minor annexin V binding (approx-
imately one order of magnitude lower). The amount of U-937
bound annexin V was not aﬀected whether the cells were sub-
Table 1
FITC-annexin V binding to lymphocytes isolated from human blood
and to three diﬀerent leukemia cell lines as determined by spectroﬂu-
orometry
Fluorescence intensity
Absolute Normalized
Normal lymphocytes 25 ± 6 1.0
K-562 238 ± 80 9.5
MOLT-4 257 ± 69 10.3
Jurkat 155 ± 69 6.2
6132 H. Schro¨der-Borm et al. / FEBS Letters 579 (2005) 6128–6134jected to trypsin treatment before the assay or not (data not
shown). For a better quantiﬁcation, the amounts of annexin
V bound to the normal lymphocytes and the leukemia cell lines
were determined spectroﬂuorometrically (Table 1). In very
good correlation to the cytotoxic activity of NK-2, the ﬂuores-
cence intensity of the cells after incubation with FITC-labeled
annexin V was extremely low for normal lymphocytes, medium
for Jurkat cells, and about 10-fold increased for the sensitive
K-562 and MOLT-4 cells, indicating a considerable amount
of PS exposed on these cells.
3.4. Intercalation of NK-2 into liposomes composed to mimick
the phospholipid composition of the cytoplasmic membrane
of normal and cancer cells
We used FRET-spectroscopy as a very sensitive model sys-
tem for peptide/membrane-interaction and to analyze the lipid
speciﬁcity of NK-2. Addition of NK-2 to liposomes prepared
from negatively charged PS resulted in a strong, dose-depen-
dent increase of the FRET signal indicating that the peptide
intercalated into the liposome membrane (Fig. 5A). In
contrast, NK-2 did not intercalate into membranes made ofA
B
Fig. 5. NK-2 intercalation into lipid vesicles as determined by FRET-
spectroscopy. The peptide was added (arrow) in the indicated amounts
to various liposomes double-labeled with NBD-PE and Rh-PE. (A)
Liposomes composed of PS. Buﬀer instead of peptide was added as a
control. (B) Liposomes composed of PC, PS, and indicated molar PC/
PS mixtures. Representative experiments each performed at least in
duplicates are shown. An intercalation of the peptide leads to an
increase of the FRET-signal (Idonor/Iacceptor).pure zwitterionic phospholipids like PC (Fig. 5B) and sphingo-
myelin (not shown), resembling the outer leaﬂet of the cyto-
plasmic membrane of normal human cells. However,
supplementing PC liposomes with PS, i.e., mimicking the sur-
face of cancer cells, enabled the eﬃcient penetration of the
liposome membrane by the peptide already at 10% PS content
(Fig. 5B).4. Discussion
The ﬁnding of the susceptibility of ﬁve of the seven tested
cancer cell lines to the peptide NK-2 is an interesting discrep-
ancy with respect to the resistance of human keratinocytes,
erythrocytes, and lymphocytes (see [12,18] and this study).
Apparently, the amount of cell surface PS contributes signiﬁ-
cantly to the susceptibility of these cells to the lytic action of
the peptide. Whereas the membrane of normal human cells is
almost free of exposed PS, and this is reﬂected also by our data
with freshly isolated human lymphocytes, the amount of PS on
the surface of cancer cells was estimated earlier to be below or
close to 10% of total phospholipids [23], i.e., up to 10-fold
higher for leukemia cells than for normal lymphocytes (Table
1). This should be suﬃcient to facilitate binding of NK-2 and
subsequent membrane destruction and may explain the target
preference of the peptide. As we could show with biomem-
brane mimetic systems, NK-2 does not interact with mem-
brane mimetics of the outer leaﬂet of normal human cells,
consisting solely of zwitterionic PC or sphingomyelin (this
study and [18,32]), but is able to intercalate into membranes
mimicking the surface of cancer cells, i.e., liposomes consisting
of a mixture of PC and PS, even if the amount of PS is rather
low (10%). Other factors than surface PS may aﬀect the sensi-
tivity of particular cells to NK-2. However, with respect to our
experiments using biomembrane mimetic model systems, a
small amount of surface exposed PS is suﬃcient to explain
the observed target selectivity.
Necrosis [8,33], as well as apoptosis via depolarization of the
mitochondrial membrane [34,35] have been described as modes
of tumor cell killing mechanisms by cationic antimicrobial pep-
tides. The dramatic changes in morphology after incubation of
the cells with the peptide NK-2 most likely are explained by a
mechanical destruction or perforation of the cellular plasma
membrane, which is in good agreement with the total loss of
structural integrity in some cells (Fig. 3). Taken into account
the fast reaction kinetics (killing within minutes), we suggest
a necrotic mechanism of NB-cell killing by NK-2.
In conclusion, NK-2 is non-toxic for normal human lym-
phocytes, whereas some cancer cells are susceptible to the pep-
tide at concentrations very similar to the antimicrobially
eﬀective dose (around 1 lM). Though NK-2 is potent and
selective in vitro, a successful systemic application cannot be
predicted at this stage. Other membranolytic peptides, which
were active against cell lines, failed in animal models. How-
ever, potency could be restored in some cases by conjugating
the peptides to binding epitopes for tumor cell speciﬁc recep-
tors, which enables a directed targeting of the peptide to the
tumor cells [36]. NK-2 seems to recognize sensitive cells
through cell surface exposure of negatively charged PS. We ob-
served a surprisingly strong correlation of NK-2 induced cell
killing with the amount of cell surface PS on various cell types.
This binding preference should allow the selective targeting of
H. Schro¨der-Borm et al. / FEBS Letters 579 (2005) 6128–6134 6133particular cancer cells in diagnostic or therapeutic means. As a
consequence of NK-2 treatment, the cellular membrane is de-
stroyed and attacked cells undergo necrotic cell death within
minutes. Antimicrobial peptides like NK-2, whose activity is
independent of tumor multi-drug resistances, could comple-
ment classical chemotherapy, or may be useful in eliminating
residual tumor cells after operative removal of solid tumors.
In combination, such a strategy would provide protection
against bacterial infections accompanying surgery. The latter
is of particular interest, since the multiple resistance of hospi-
talized germs to common antibiotics is likely to be surmounted
by the mechanism of NK-2, which clearly is diﬀerent to that of
conventional antibiotics.
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